PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
Status:
WITHDRAWN
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
This study is investigating the optimal dose and the advantage in combining investigational immunotherapy drugs known as Retifanlimab, INCAGN02385 and INCAGN02390 to improve the responses to CAR T-cell therapy. Additionally, the study will investigate that triple checkpoint blockade of PD-1, TIM-3 and LAG-3 molecules will overcome CAR T-cell therapy resistance in patients with suboptimal responses.